Mumbai: Pharma company Wockhardt Ltd said on 20 June it has received US Food and Drug Administration (USFDA) approval for Cefprozil tablets, an antibiotic in multiple strengths, and is all set to launch the product in the US.
“Cephalosporins have been an important product in our portfolio and Cefprozil will be a good addition to this range with a market potential of around $51 million”, Wockhardt Chairman Habil Khorakiwala said.
The USFDA approval for Cefprozil tablets was for strengths of 250 mg and 500 mg.
Cephalosporin class of antibiotics, is used in the treatment of respiratory tract and skin infections and is the generic version of brand Cefzil, sold by Bristol Myers Squibb.
“The eight FDA approval in just four months will significantly contribute to our growing visibility in the US”, Habil Khorakiwala added.
The Cefprozil tablets are manufactured at Wockhardt’s USFDA certified formulation plant at Waluj, Maharashtra, and the product was developed in-house.
Shares of Wockhardt were trading at Rs 396.25, up 1.12 per cent on BSE in morning trade.